If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiscoverIE Regulatory News (DSCV)

Share Price Information for DiscoverIE (DSCV)

Share Price is delayed by 15 minutes
Get Live Data
683.00    7.00 (1.04%)
Bid:
684.00
Ask:
686.00
Spread: 2.00 (0.292%)
Market Cap: £656.55m
DSCV Live PriceLast checked at - London Stock Exchange

Intraday DiscoverIE Share Chart

Director/PDMR Shareholding

1 Jul 2014 14:14

RNS Number : 1028L
Acal PLC
01 July 2014
 



1 July 2014

 

Acal plc

 

Directors' Shareholdings

 

 

 

Acal plc (LSE : ACL, "Acal" or the "Group"), a leading European specialist electronics supplier, announces that it was notified yesterday and today of the following acquisitions of the Company's ordinary shares by Directors of the Company and their connected persons. These acquisitions took place pursuant to the 1 for 1 rights issue at 176 pence per new ordinary share announced by the Company on 5 June 2014.

 

Name

Ordinary shares acquired pursuant

to rights issue

Total holding

following rights

issue

Percentage held

of enlarged issued share capital

Richard Moon 1

23,800

47,600

0.07

Nicholas Jefferies

36,898

73,796

0.12

Simon Gibbins

14,365

28,730

0.04

Graham Williams

19,450

38,900

0.06

Richard Brooman

4,000

8,000

0.01

 

1 The Company has been notified by Richard Moon that he has acquired 14,000 ordinary shares at a price of 385.88 pence per share. This acquisition is included in the totals of ordinary shares shown against his name above. He is also interested in Synergie Business Limited's holding of 20,000 ordinary shares in the Company (total holding following rights issue) because he is the Chairman of, and a shareholder in, that company. Consequently, following the rights issue, he will be interested in 67,600 ordinary shares in the Company (0.11% of the enlarged issued share capital).

 

 

For further information please contact:

 

Acal plc

01483 544500

Nick Jefferies

-

Group Chief Executive

Simon Gibbins

-

Group Finance Director

Instinctif Partners

0207 457 2020

Mark Garraway

Helen Tarbet

 

 

 

Notes to Editors:

 

About Acal plc

 

Acal is a European leader in specialist electronics, designing, manufacturing and distributing specialist electronic, photonic and medical products for the industrial and healthcare sectors. It is the only such provider with an infrastructure to deliver a broad range of specialist products and bespoke solutions across Europe. The Electronics division has completed seven acquisitions in the last four years, more than trebling its specialist revenues. Acal's strategy is to further enhance its leadership position through organic growth, complementary acquisitions and continued enhancement of its customer service capabilities. The division has operating companies across Europe including the UK, Germany, France, Benelux, Italy, Poland, Spain and the Nordic region as well as in Asia (China and South Korea) and Africa (South Africa). Businesses comprise Acal BFi, Hectronic, MTC, Myrra Group, RSG, Stortech and Vertec.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFLVDLILIIS
Date   Source Headline
15th Sep 20239:11 amRNSDirector/PDMR Shareholding
13th Sep 20237:00 amRNSAcquisition of 2J Antennas Group
5th Sep 20232:17 pmRNSNotification of Major Holdings
31st Aug 20237:00 amRNSAcquisition completion - Silvertel
1st Aug 20237:00 amRNSAcquisition of Silvertel
24th Jul 20232:31 pmRNSResults of Annual General Meeting
24th Jul 20237:00 amRNSTrading Update
27th Jun 202310:53 amRNSDirector / PDMR Shareholding
27th Jun 202310:47 amRNSNotification of Major Holdings
22nd Jun 202312:35 pmRNSAnnual Report & Notice of AGM
19th Jun 20238:35 amRNSNotification of Major Holdings
15th Jun 20239:51 amRNSDirector LTIP Award
7th Jun 20237:00 amRNSPreliminary results
1st Jun 20232:50 pmRNSNotification of Major Holdings
30th May 20237:00 amRNSAppointment of Non-Executive Director
18th May 20231:33 pmRNSNotification of Major Holdings
17th May 202310:25 amRNSNotice of Full Year Results
19th Apr 20237:00 amRNSFull Year Trading Update
18th Apr 20237:00 amRNSNotification of Major Holdings
29th Mar 20235:47 pmRNSNotification of Major Holdings
15th Mar 20233:53 pmRNSNotification of Major Holdings
15th Mar 20238:37 amRNSNotification of Major Holdings
15th Mar 20237:00 amRNSNotification of Major Holdings
23rd Feb 20232:58 pmRNSNotification of Major Holdings
20th Feb 20239:48 amRNSNotification of Major Holdings
15th Feb 20235:33 pmRNSNotification of Major Holdings
13th Feb 202311:36 amRNSNotification of Major Holdings
25th Jan 20237:00 amRNSQ3 Trading Update and Acquisition Completion
6th Jan 20231:41 pmRNSNotification of Major Holdings
6th Jan 20238:24 amRNSNotification of Major Holdings
3rd Jan 202310:38 amRNSNotification of Major Holdings
22nd Dec 20227:00 amRNSAcquisition of Magnasphere Corporation
14th Dec 20224:31 pmEQSParadigm Biopharmaceuticals (PAR): Adapted therapies to meet unmet demand
5th Dec 20229:53 amEQSdiscoverIE Group (DSCV): Focused on sustainable growth
2nd Dec 202212:58 pmRNSNotification of Major Holdings
2nd Dec 20228:37 amRNSNotification of Major Holdings
23rd Nov 202212:01 pmEQSdiscoverIE Group profits jump in 'very strong first half'
23rd Nov 20227:00 amRNSdiscoverIE Commits to Net Zero Emissions
23rd Nov 20227:00 amRNSInterim Results
21st Nov 20223:38 pmRNSNotification of Major Holdings
16th Nov 20228:58 amRNSTR-1: Notification of Major Holdings
14th Nov 20223:41 pmRNSIssue of Equity & Total Voting Rights
1st Nov 202212:08 pmRNSNotice of Half Year Results
1st Nov 20227:00 amRNSDirectorate Changes
14th Oct 20224:56 pmRNSNotification of Major Holdings
13th Oct 20223:31 pmRNSTR-1: Notification of major holdings
13th Oct 20227:00 amRNSFirst Half Trading Update
11th Oct 202211:42 amRNSNotification of Major Holdings
5th Oct 20227:52 amRNSNotification of Major Holdings
5th Oct 20227:52 amRNSNotification of Major Holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.